Title

3D MR spirometry in adults with COPD against reversibility testing

Leading partner

APHP

Work Package

WP1

Sites

Institute of Cardiometabolism and Nutrition (ICAN), La Pitié-Salpêtrière Hospital, Paris, France

Population

30 adults (15 women and 15 men) with COPD with differing severity will be recruited prospectively within their follow-up program to undergo spirometry and 3D MR spirometry on the same day before and after BD reversibility test (inhalation of short-acting β2-sympathomimetics BD such as inhaled salbutamol).

Objectives

1. Validate 3D MR spirometry against spirometry in COPD patients
2. Assess the sensitivity of 3D MR spirometry to COPD severity
3. Assess the regional lung structural and functional changes with COPD severity using 3D MR spirometry
4. Evaluate the regional lung mechanics with respect to COPD severity using 3D MR spirometry
5. Assess the sensitivity of 3D MR spirometry to bronchodilator (BD) responsiveness of COPD patients
6. Establish reference flow-volume loop maps in COPD patients with 3D MR spirometry

Examination

All included patients will have spirometry and 3D MR spirometry performed the same day at La Pitié-Salpêtrière Hospital. MRI scans will be acquired using a MR compatible spirometer for reference. Spirometry will be performed in two positions (sitting and supine) and over three types of respiration (spontaneous, slow, and forced).
3D MR spirometry will be performed on a 1.5 T MR imaging system (Siemens Healthineers) at La Pitié-Salpêtrière Hospital. Patients will breath freely in a supine position during MR acquisition. Dynamic 3D lung images will be reconstructed (WP1) and processed (WP2) by UPSaclay to primarily provide maps of flow-volume loops and maps of fractional anisotropy strain metric.